Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Revenue (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Revenue for 6 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 35.99% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.7 million, a 134.45% decrease, with the full-year FY2024 number at $200000.0, down 93.96% from a year prior.
  • Revenue was $1.2 million for Q3 2025 at Marker Therapeutics, up from $861184.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $2.5 million in Q1 2023 to a low of -$4.1 million in Q4 2024.
  • A 4-year average of $686577.7 and a median of $861184.0 in 2025 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 647.66% in 2024; the steepest drop was 1579.42% in 2024.
  • Marker Therapeutics' Revenue stood at $759143.0 in 2022, then tumbled by 132.47% to -$246473.0 in 2023, then crashed by 1579.42% to -$4.1 million in 2024, then soared by 129.79% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Revenue are $1.2 million (Q3 2025), $861184.0 (Q2 2025), and $349104.0 (Q1 2025).